Navigation Links
CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
Date:2/16/2011

KING OF PRUSSIA, Pa. and MONTREAL, Feb. 16, 2011 /PRNewswire/ -- As a means of aiding the World Federation of Hemophilia's (WFH) progress in improving the diagnosis and treatment of hemophilia in developing countries through its Global Alliance for Progress (GAP) program, CSL Behring has committed to donating more factor VIII concentrate (FVIII) to WFH. The donated product will be used in South America, Thailand, the Philippines, parts of eastern Europe, parts of the Middle East, and in Tunisia. The donation, the total market value of which is approximately $500,000, will be made using coagulation factor concentrate with a minimum shelf-life of one year.

CSL Behring has pledged to support the WFH with separate financial contributions totaling nearly $1 million over a period of three years. This most recent donation is part of that commitment.

"As a long-standing contributor to GAP, CSL Behring is pleased to once again be in a position to assist hemophilia patients who have a critical need for safe, effective medical therapies," said Peter Turner, President and Chief Executive Officer of CSL Behring. "We are also gratified to be a partner with WFH in this effort, an organization that continues to make a large and positive difference in the world. Our commitment to their progress remains strong."

"The WFH relies on product donations to help introduce clotting factor concentrates in developing countries and these donations serve as a catalyst for improving care," said Claudia Black, Chief Executive Officer of the WFH. "We are grateful to our industry partners such as CSL Behring, who provide, among other resources, valuable and life-saving medicine, including this most recent donation of coagulation factor. "

Factor VIII is an essential blood clotting factor that can be given to hemophiliacs to restore hemostasis.

About the Global Alliance for Progress The Global Alliance for Progress (GAP) is a 10-year healthcare development program, launched in April 2003. GAP's goal is to greatly increase the diagnosis and treatment of people with hemophilia and other bleeding disorders in developing countries.

The program aims to close the gap between the number of people born with hemophilia and those who reach adulthood, the gap between the estimated and actual number of people diagnosed with bleeding disorders, and the gap between the amount of treatment product needed versus what is available.

GAP partners include CSL Behring, Baxter, Bayer, Biogen Idec Hemophilia, Biotest, Pfizer, Talecris, the Irish Hemophilia Society, the Jan Willem Andre de la Porte Family Foundation, and the World Health Organization (WHO).

Sixteen countries have participated in GAP: Armenia, Azerbaijan, Belarus, China, Ecuador, Egypt, Georgia, Jordan, Lebanon, Mexico, Peru, Philippines, Russia, Syria, Thailand, and Tunisia.

About the World Federation of Hemophilia The World Federation of Hemophilia (WFH) is an international not-for-profit organization dedicated to improving the lives of people with hemophilia and other inherited bleeding disorders.

Since it was established in 1963, the WFH has grown into a truly global network with member organizations in 118 countries and official recognition from the World Health Organization. It works in partnership with healthcare professionals and people with hemophilia, governments and regulators, industry and foundations, to improve care for people with bleeding disorders throughout the world. For more information, visit www.wfh.org.

About CSL Behring CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.Sheila A. Burke, Director, Communications & Public RelationsWorldwide Commercial OperationsCSL BehringC: 484-919-2618O: 610-878-4209Sheila.Burke@cslbehring.com
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
2. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
3. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
4. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
5. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
6. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
7. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
8. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Nations Laboratory Response Network Marks First Decade of Protecting Public Health
11. Clinical Study Proves Pollogens TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch Marks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):